119-HR-5160 Journalist Public Summary

Headline Summary

Bipartisan bill to keep the national bone marrow and cord blood donor programs funded and operating through 2031, with a modest funding increase.

What It Does

The bill renews the Stem Cell Therapeutic and Research Act programs that connect patients with lifesaving bone marrow and cord blood transplants. It authorizes $33,009,000 per year for fiscal years 2027–2031 for the C.W. Bill Young Cell Transplantation Program and extends the National Cord Blood Inventory effort from 2026 to 2031. In plain terms: it keeps the national donor registry and cord blood banks running and accessible.

Who’s For It

• Lead sponsor: Rep. Chris Smith (R–NJ), with bipartisan co-sponsors Reps. Doris Matsui (D–CA), Gus Bilirakis (R–FL), Chellie Pingree (D–ME), Claudia Tenney (R–NY), and Kweisi Mfume (D–MD).
• Broad bipartisan support signaled by a unanimous 48–0 committee vote.
• Supporters argue the programs save lives by maintaining a national donor registry, coordinating matches, and sustaining a diverse cord blood inventory so more patients—especially those from underrepresented groups—can find compatible donors.

Who’s Against It

• No recorded opposition at the committee stage (vote was unanimous).
• Possible concerns that could arise on the floor include questions about federal spending priorities, duplication with other efforts, or program oversight—not about embryonic stem cell research, since this bill deals with bone marrow and cord blood transplants.

What’s Next

As of May 29, 2026, the bill has been ordered reported by the House Energy and Commerce Committee and now awaits consideration by the full House. If it passes the House, it will move to the Senate; if both chambers approve, it goes to the President for signature.